CagriSema vs VIP (Vasoactive Intestinal Peptide)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
CagriSema
CagriSema is a fixed-ratio combination of cagrilintide (a long-acting amylin analog) and semaglutide, developed by Novo Nordisk. By combining two distinct appetite-regulating peptide hormones, CagriSema aims to achieve greater weight loss than semaglutide alone. Phase 3 data showed 22.7% body weight reduction, and an FDA response is expected in 2026.
Full details →VIP (Vasoactive Intestinal Peptide)
VIP is a 28-amino acid neuropeptide with wide-ranging effects throughout the body. It acts as a neurotransmitter, neuromodulator, and immune regulator with particular importance in gut and lung function.
Full details →Side-by-Side Comparison
| Aspect | CagriSema | VIP (Vasoactive Intestinal Peptide) |
|---|---|---|
| Mechanism | CagriSema combines two complementary peptide mechanisms: (1) Semaglutide — GLP-1 receptor agonist providing glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and hypothalamic appetite suppression. (2) Cagrilintide — a long-acting analog of amylin, a peptide hormone co-secreted with insulin from pancreatic beta cells. Amylin activates amylin receptors (calcitonin receptor + RAMP complexes) in the area postrema and hypothalamus, providing additional appetite suppression via a distinct neuronal pathway from GLP-1. The combination produces additive weight loss by engaging two independent satiety signaling systems. | Binds to VPAC1 and VPAC2 receptors to modulate immune responses, regulate circadian rhythms, promote vasodilation, and support barrier function in gut and lungs. Has potent anti-inflammatory effects. |
| Typical Dosage | Phase 3 trial doses: cagrilintide 2.4 mg + semaglutide 2.4 mg weekly (fixed combination in a single injection). Dose escalation: start at cagrilintide 0.15 mg / semaglutide 0.25 mg weekly and escalate over 16 weeks to the maintenance dose. Administered as a single injection combining both peptides. | Intranasal: 50-200mcg 1-3 times daily for chronic inflammatory conditions. Some protocols use subcutaneous administration. Dosing varies by condition. |
| Administration | Single subcutaneous injection once weekly, combining both peptides. Pre-filled pen device. Not yet commercially available. FDA response expected 2026. | Intranasal is most common for inflammatory conditions. Subcutaneous injection also used. Must be stored cold and protected from light. |
| Side Effects | Phase 3 data: nausea, vomiting, diarrhea, constipation (similar profile to semaglutide alone, but some reports suggest modestly higher GI rates). Decreased appetite. Injection site reactions. | May cause nasal irritation, flushing, headache, or temporary diarrhea. Generally well-tolerated at standard doses. |
| Best For |
Key Differences
Unique to CagriSema:
Unique to VIP (Vasoactive Intestinal Peptide):
Detailed Analysis
Commonalities
CagriSema and VIP (Vasoactive Intestinal Peptide) are used for different purposes and have limited overlap in their applications.
Which Should You Choose?
Choose CagriSema for Weight Loss, Diabetes Management. Choose VIP (Vasoactive Intestinal Peptide) for Sleep Quality, Immune Support, Gut Health.
Ready to Learn More?
Looking for trusted sources?